The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix

Similar documents
Trophoblastic tumors

The clinically challenging entity of liver metastasis from tumors of unknown primary

Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review

05/07/2018. Types of challenges. Challenging cases in uterine pathology. Case 1 ` 65 year old female Post menopausal bleeding Uterine Polyp

Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases

Differential diagnosis of HCC

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

Histopathological diagnosis of CUP

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Reporting of carcinoma of unknown primary tumour (CUP)

ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016

Dr Sanjiv Manek Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Circulation: X Case number: 501 Number of responses: 84 Date: 4 MAY 12

Index. Cytoplasm, nonepithelial malignant tumor features 70

Lung Tumor Cases: Common Problems and Helpful Hints

ENODMETRIAL CARCINOMA: SPECIAL & NOT SO SPECIAL VARIANTS

NEW IHC A n t i b o d i e s

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

New Developments in Immunohistochemistry for Gynecologic Pathology

CASE 4 21/07/2017. Ectopic Prostatic Tissue in Cervix. Female 31. LLETZ for borderline nuclear abnormalities

Presenter: Yeh-Han Wang M.D.

What I Learned from 3 Cases and 3 Antibodies

The PAX8 gene is a member of the paired-box family of

INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS. Gabor Fischer Diagnostic Services Manitoba University of Manitoba

History A 89 year old gentleman presenting with a scalp/forehead nodule. Patient had squamous cell carcinoma 18 m at same site, excised. Outside diagn

Enterprise Interest None

When Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box?

IHC Panels as an Aid in Diagnostic Decision Making

of 20 to 80 and subsequently declines [2].

Ovarian Clear Cell Carcinoma

Nordic Immunohistochemical Quality Control

I have nothing to disclose

Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012

Effusion Cytology: Diagnostic Challenges

3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project

What really matters When and Why. Pathology of Uterine Mesenchymal Lesions. Nafisa Wilkinson London

Mu ath M.A. Rjoub Supervised by: Dr. Huda Zahawi, FRCPath. King Abdullah University Hospital )KAUH(

Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors

PATOLOGIA MOLECULAR DEL CANCER DE ORIGEN DESCONOCIDO? Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.

Technology from Abcam

Adenocarcinoma of the Cervix

Current Concept in Ovarian Carcinoma: Pathology Perspectives

In situ and Invasive Endocervical Carcinoma: Problems and Pitfalls in Diagnosis

Interesting Cases in Gynecologic Pathology. Michael Ward, MD Surgical Pathology Fellow University of Utah Health Sciences Center Salt Lake City, UT

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)

CASO 1. Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.

Immunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Endometrial pathology. Dr Tom Dodd and Dr Georgina England

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

The available immunohistochemical stains and their

Diagnostic IHC in lung and pleura pathology

TEST MENU BY SPECIALTY

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Carcinoma of unknown primary origin (CUP) is defined

Problem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships

Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

Enterprise Interest Nothing to declare

Diagnostically Challenging Cases in Gynecologic Pathology

Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome

Ascitic Fluid and Use of Immunocytochemistry. Mercè Jordà, University of Miami

Case 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:

Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia

2018 ICD-O-3 Updates in Table Format with Annotation for Reference

Impact of immunostaining of pulmonary and mediastinal cytology

Endometrial Stromal Tumors

Ovarian carcinoma classification. Robert A. Soslow, MD

Simultaneous de-waxing and standardisation of antigen retrieval in immunohistochemistry using commercially available equipment

Scotland and Northern Ireland EQA Scheme. Circulation 46

Intravascular Endometrium Mimicking Vascular Invasion

Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia

64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus

In Situ Hybridization Immunohistochemistry

Classification (1) Classification (3) Classification (2) Spindle cell lesions. Spindle cell lesions of bladder (Mills et al.

Type I. Type II. Excess estrogen Lynch Endometrioid adenocarcinoma PTEN. High grade More aggressive Serous, Clear Cell p53

2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Mesothelioma Pathobasic. Lukas Bubendorf Pathology

Cytology and Surgical Pathology of Gynecologic Neoplasms

Case Report Clinicopathologic study of endometrial dedifferentiated endometrioid adenocarcinoma: a case report

Carcinoma of Unknown Primary (CUP)

Neuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:

Serous effusion Objectives. Cytology of Serous Effusions From basics to challenges

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Financial disclosures

In the past several years, significant progress has been

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases

Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources

Enterprise Interest No disclosures.

I. Diagnosis of the cancer type in CUP

CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY

Transcription:

The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

Cervix Low-grade squamous intraepithelial lesion High-grade squamous intraepithelial lesion Squamous cell carcinoma Adenocarcinoma (endocervical, usual type; mucinous; villoglandular; endometrioid; clear cell; mesonephric) Benign glandular lesions Neuroendocrine carcinoma Soft tissue tumors Melanoma Hematological malignancies Metastases

SIL vs. reactive Ki-67 p16: clone E6H4 Ki-67: clone MIB1 p16

AIS vs. hyperplasia and reactive changes Ki-67 p16: clone E6H4 Ki-67: clone MIB1 p53: clone DO-1 p16

Cervix adenoca. vs. SqCC vs. ASq ca. CK8: clone C51 Not useful Ber-EP4: clone Ber-EP4 CEA CK5/6: clone D5/16B4 p16 p63: clone 4A4 CK7 p40: rabbit polyclonal

SqCC p40 p63 CK5/6 CK8 Ber-EP4

Carcinoma, NOS CK8 Ber-EP4 CK5/6 p40 p63

Neuroendocrine carcinoma Chromogranin A Synaptophysin Synaptophysin: clone 27G12 Chromogranin A: clone MAB5268

Avoid CD56 CD56 CD56 HGSC

Clear cell carcinoma - cervix p53 mcea HNF1β Napsin p16 p16: clone E6H4 p53: clone DO-1 HNF1β: polyclonal rabbit Napsin A: clone TMU-Ad02

Mesonephric carcinoma EMA: clone E29 Vimentin: clone 3B4 Calretinin: clone Calret1 CD10: clone 56C6 (PAX8, TTF1, p16: +/-) (mcea, ER, PR: negative)

Mesonephric carcinoma EMA p16 PAX8 EMA: clone E29 Vimentin: clone 3B4 CA 125: clone M11 p16: clone E6H4 PAX8: rabbit polyclonal CA 125 Vimentin

Corpus uteri Adenocarcinoma (endometrioid; mucinous; clear cell, serous; neuroendocrine; mixed; undifferentiated; dedifferentiated) Carcinosarcoma Leiomyoma Sarcoma (ESS, LMS, Undifferentiated HGUS, RMS) Other soft tissue tumors (PECOMA, UTROSCAT) Trophoblastic tumors Invasion of gynecologic tumors of other origin Metastases

Endometrioid Serous Clear cell

Endometrial carcinoma Matias-Guiu and Davidson, Virchows Arch 2014;464:315-331

Differentiating uterine AC of various histology ER: clone 6F11; positive in the majority of EC and in some SC, negative in CCC PR: clone 16; positive in the majority of EC and in some SC, negative in CCC p16: clone E6H4; patchy in EC, diffusely positive in SC, variable in CCC p53: clone DO-1; aberrant in SC + in some EC and CCC HNF1β: polyclonal rabbit; positive in CCC and some EC, usually negative in SC PTEN: clone 6H2.1; negative in majority of EC, positive in SC and CCC ARID1A: polyclonal rabbit; negative in 50% of EC and CCC, positive in SC Napsin A: clone TMU-Ad02; positive in CCC, negative in other histotypes Other: Vimentin: clone 3B4; positive in EC, variable in SC, often negative in CCC Ki-67: clone MIB1; high score in SC and CCC + in some EC mcea: clone II-7; focally positive in EC, negative in SC and CCC

Serous carcinoma p16 p53 p16: clone E6H4 p53: clone DO-1

Serous carcinoma ER p16 p53 ER: clone 6F11 p16: clone E6H4 p53: clone DO-1

Clear cell carcinoma HNF1β p53 p16 mcea Vimentin ER PR ER: clone 6F11 PR: clone 16 p16: clone E6H4 p53: clone DO-1 mcea: clone II-7 HNF1β: polyclonal rabbit Vimentin: clone 3B4

Endometrioid and clear cell carcinoma HNF1b ER PR p53 ER: clone 6F11 PR: clone 16 p53: clone DO-1 HNF1β: polyclonal rabbit

Endometrioid/serous carcinoma ER PR p53 p16 ER: clone 6F11 PR: clone 16 p16: clone E6H4 p53: clone DO-1

Serous ARID1A Endometrioid Clear cell Clear cell ARID1A: rabbit polyclonal

Serous PTEN Serous Endometrioid Endometrioid PTEN: clone 6H2.1

IMP2 & IMP3 IMP2 IMP2 IMP3 IMP3 IMP3 IMP3 IMP3 IMP2: rabbit polyclonal IMP3: clone N-19

Spindle cell tumor panel Actin: clone HHF35 Desmin: clone D33 SMA: 14D S100: polyclonal rabbit EMA: clone E29 Pan-cytokeratin: clone AE1/AE3 CD31: clone JC/70A CD34: QBEND-10 CD68: clone KP-1 CD99: clone EPR3097Y (rabbit)

Actin: clone HHF35 Desmin: clone D33 SMA: 14D h-caldesmon: clone h-cd CD10: clone 56C6 ESS vs. LMS Sub-optimal!

ESS vs. LMS SMA - ESS Desmin - LMS H-Caldesmon - ESS

ESS with sex cord pattern AE1/AE3 Vimentin Inhibin ER CD10 Pan-cytokeratin: clone AE1/AE3 Vimentin: clone 3B4 Inhibin: clone R1 ER: clone 6F11 (also clones SP1 and EP1) CD10: clone 56C6

CD10 ESS LMS Small cell sarcoma Small cell sarcoma

Potential markers? Davidson et al., Gynecol Oncol 2013;128:349-55 LMS: fatty acid binding protein-3 (FABP3), transgelin (TAGLN), neuron navigator 2 (NAV2); ESS: Cyclin D2 (CCND2), integral membrane protein 2A (ITM2A)

High-grade vs. low-grade ESS Cyclin D1 HG Cyclin D1 HG Cyclin D1 LG Cyclin D1: clone SP4

HG sarcoma with RMS areas Myf-4 Actin Desmin Myogenin Myf-4: clone LO26 Myogenin: clone F5D

PECOMA HMB-45 HMB-45 HMB-45: clone HMB45

Complete mole p57 p57: clone 25B2

Partial mole p57 p57: clone 25B2

Epithelioid Trophoblastic Tumor (ETT) PLAP p63 hpl p63: clone 4A4 PLAP: clone 8A9 hpl: rabbit monoclonal

Choriocarcinoma presenting as SqCC

Choriocarcinoma presenting as SqCC Pan-CK Vimentin Pan-CK: clone AE1/AE3 Vimentin: clone 3B4 HCG: rabbit polyclonal HCG

HCG-producing SqCC EMA CK5/6 CK8 HCG EMA: clone E29 CK5/6: clone D5/16B4 CK8: clone C51 HCG: rabbit polyclonal

Other

Melanoma Melan A: clone A103 HMB-45: clone HMB45 S100: polyclonal rabbit Vimentin: clone 3B4 Pan-cytokeratin: clone AE1/AE3

Melanoma HMB45 Melan A AE1/AE3 Vimentin

Diffuse large B-cell lymphoma CD20 CD79a MUM1 PAX5 CD20: clone L-26 CD79a: clone JCB-117 MUM1: clone MUM1p PAX5: clone 24/PAX5

Myelosarcoma CD15 MPO Ki-67 CD68 CD15: clone Carb-3 MPO: rabbit monoclonal Ki-67: clone MIB1 CD68: clone KP-1

Local extension and metastasis

Vaginal recurrence of endometrial carcinoma ER PR DD from primary AC in cervix ER: clone 6F11 (also clones SP1 and EP1) PR: clone 16 Vimentin: clone 3B4 mcea: clone II-7 p16: clone E6H4 HPV analysis

Lobular breast ca. CK8 ER PR GCDFP-15 CK8: clone C51 ER: clone 6F11 (also clones SP1 and EP1) PR: clone 16 GCDFP-15: clone 23A3

Appendiceal NET in cervix

Appendiceal NET in cervix mcea mcea CK20 Synaptophysin CDX2 Chromogranin A Synaptophysin: clone 27G12 Chromogranin A: clone MAB5268 mcea: clone II-7 CDX2: clone DAK-CDX2 CK20: clone Ks20.8

Urothelial carcinoma in vagina URO III CK20 CK20: clone Ks20.8 GATA3: clone L50-823 URO III: clone AU1

Granulosa cell tumor in vagina Inhibin Calretinin SF-1 (ovary) SF-1 (ovary) Inhibin: clone R1 Calretinin: clone Calret1 SF-1: clone 1665 (FOXL2)

HGSC met. to cervix WT1 ER p53 mcea WT1: clone 6F-H2 ER: clone 6F11 (also clones SP1 and EP1) p53: clone DO-1 mcea: clone II-7

HGSC met. to cervix Ber-EP4 WT1 WT1: clone 6F-H2 Ber-EP4: clone Ber-Ep4

Take-home message Morphology is the basis for diagnosis There is overlap in the immunophenotype of epithelial lesions in the cervix and corpus Metastases and rare entities should be in the differential diagnosis Molecular methods are likely to play a role in future diagnostics

Acknowledgements IHC lab, Oslo University Hospital Dr. Elin Borgen, MD PhD Inger Johanne Ryen, MSc

Thank you for your attention